24-week Open-label Extension Study Evaluating PXT00864 Effect in Mild AD Patients Further to PLEODIAL-I Completion

24-week Open-label Extension Study Evaluating the Effect of PXT00864 in Mild Alzheimer's Disease Patients Further to PLEODIAL-I Completion

PLEODIAL-II study is an extension of the previous pilot PLEODIAL-I study (CLN-PXT00864-03 protocol) and is designed for the descriptive analysis of patients with mild AD who are exposed to PXT00864 over an additional 24-week period.

Patients having completed the previous 12-week PLEODIAL-I study were eligible to receive PXT00864 in this 24-week open-label extension PLEODIAL-II study in order to collect some additional long-term data regarding the safety and the potential effect of PXT00864 on cognitive and behavioural impairments.

Main Inclusion Criteria:

• Mild Alzheimer's Disease patient who was included in PLEODIAL-I study
• Mini Mental State Examination (MMSE) score greater or equal to 20

Main Exclusion Criteria:

• Patient who was not compliant with the previous PLEODIAL-I study protocol
• Patient who experienced significant adverse events which necessitated treatment discontinuation during the PLEODIAL-I study